Clinical Trials Logo

Filter by:
NCT ID: NCT05184673 Completed - Physical Activity Clinical Trials

Moderate Aerobic Activity Through Yoga

MAT
Start date: June 8, 2021
Phase: N/A
Study type: Interventional

The 2018 Physical Activity Guidelines for Americans (PAGA) recommend 150 minutes of moderate intensity activity for adult (18 years and older) Americans to promote health. PAGA also recommends that older adults (65+) engage in multicomponent and balance exercises weekly as a way to reduce falls and injuries from falls. This recommendation includes yoga, however, the current research and recommendations on using yoga to meet moderate intensity activity guidelines is limited. This study will utilize heart rate monitoring to determine if certain styles of yoga can be used to meet the PAGA.

NCT ID: NCT05184452 Completed - HIV Infections Clinical Trials

A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants

Start date: November 15, 2021
Phase: Phase 1
Study type: Interventional

Part A: The purpose of this part of the study is to understand how the body's immune system responds to a new lab-made antibody against HIV. The study is looking to see if the way the antibody is given affects the immune response. The study will also look at whether the antibody is safe to give to people and does not make them too uncomfortable. Part B: The purpose of this part of the study is to understand how the body's immune system responds to lab-made antibodies against HIV when they are given in combination at different doses. The study also wants to see if the way the antibodies are given affects the immune response.

NCT ID: NCT05184192 Completed - COVID-19 Clinical Trials

Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

GRACE
Start date: January 10, 2022
Phase: Phase 2
Study type: Interventional

This study will investigate the efficacy of oral gabapentin in olfactory improvement following Covid-19- associated olfactory dysfunction. This is a randomized, double-blinded, placebo-controlled trial.

NCT ID: NCT05183919 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Software Treatment for Actively Reducing Severity of ADHD in Adults (STARS ADHD Adult)

Start date: November 29, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effects of the videogame-like digital therapy on attentional functioning and symptoms in Adults diagnosed with ADHD.

NCT ID: NCT05183282 Completed - Lagophthalmos Clinical Trials

Nictavi Tarsus Patch for Managing Lagophthalmos

Start date: March 30, 2022
Phase: N/A
Study type: Interventional

Lagophthalmos is the inability to completely close the eyelids, which can be caused by conditions such as facial nerve dysfunction and eyelid scarring. Lagophthalmos causes evaporation of the tears, which in turn can lead to damage to the eye and permanent vision loss. Surgical interventions such as tarsorrhaphy or gold/platinum weight implantation can improve lagophthalmos, but these are invasive procedures that are not easily reversible. Temporary methods for treating lagophthalmos are also available, such as the use of medical tape or commercial eyelid closure devices. In the investigators' clinical experience, however, these methods are not well-tolerated by patients due to discomfort, especially due to the device sticking to the eyelashes. As a result, patients are at greater risk of non-compliance and subsequently experiencing ocular complications. The Nictavi Tarsus Patch is a new medical device that uses a flexible material that conforms to the upper eyelid curvature while maintaining sufficient rigidity to keep the upper eyelid in a closed position. It also is designed to be placed above the eyelash line, which allows for enhanced comfort. There has been no study to date evaluating the Tarsus Patch for its effectiveness, safety, or tolerability. The purpose of this study is to determine the effectiveness, safety, and tolerability of the Tarsus Patch in managing lagophthalmos in children and adolescents overnight. The investigators hypothesize that there will be a significant improvement in eyelid closure when using the Tarsus Patch when compared to not using any device and that over 90% of subjects will achieve complete eyelid closure with its use. The investigators also hypothesize there will be no complications related to the use of the Tarsus Patch, and that it will be considered by patients and parents to be comfortable, easy to use, and, overall, preferable to other available methods of nocturnal eyelid closure.

NCT ID: NCT05183113 Completed - Clinical trials for Spinal Cord Injuries

Measuring the Neurological Benefits of Intermittent Hypoxia Therapy With MRI

Start date: May 20, 2019
Phase: N/A
Study type: Interventional

This study uses Magnetic Resonance Imaging to image the brain and spinal cord before and after an Intermittent Hypoxia intervention. Acquiring these scans in patients with chronic cervical spinal cord injury and uninjured controls will enable characterization of changes in neurovascular physiology caused by this promising new therapy.

NCT ID: NCT05183087 Completed - Clinical trials for Traumatic Brain Injury

Long-Term Effects of Repetitive, Low-Level Blast Exposure on Special Operations Forces Service Members

ReBlast
Start date: July 1, 2021
Phase:
Study type: Observational

This is a pilot study to identify biomarkers that individually, and in combination, demonstrate the greatest sensitivity to repetitive, low-level blast exposure (RLLBE) neurotrauma in Special Operations Forces (SOF) personnel. The proposed cross-sectional, multimodal study will elucidate the potential effects of long-term RLLBE by comparing biomarkers across subjects.

NCT ID: NCT05183022 Completed - Dry Eye Clinical Trials

Total30 Sphere Contact Lenses

Start date: January 3, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to map comfort over the full wear day in established, asymptomatic, soft CL wearers who are refit in Total30 Sphere CLs.

NCT ID: NCT05182840 Completed - Clinical trials for Kidney Disease, Chronic

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Start date: January 11, 2022
Phase: Phase 2
Study type: Interventional

This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combination with a medicine called empagliflozin. In the first part of the study, participants take empagliflozin or placebo as tablets every day for 2 months. Placebo tablets look like empagliflozin tablets but do not contain any medicine. In the second part, participants are divided into several groups. Depending on the group, the participants then additionally take different doses of BI 690517 or placebo as tablets for 3.5 months. In this case, placebo tablets look like BI 690517 tablets but do not contain any medicine. Participants are in the study for about 6 months. During this time, they visit the study site about 12 times. Where possible, about 4 of the 12 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call. Participants collect urine samples at home. These samples are then analysed to assess kidney function. At the end of the trial the results are compared between the different groups. The doctors also regularly check participants' health and take note of any unwanted effects.

NCT ID: NCT05182554 Completed - COVID-19 Pandemic Clinical Trials

COVID-19 Messaging for Vaccination

Start date: December 22, 2021
Phase: N/A
Study type: Interventional

This study will distribute videos of health professionals encouraging Covid-19 vaccination to a large sample of Facebook users, and will test the most effective ways to maximize diffusion of this vaccine-related content to increase vaccination rates. The study sample will be U.S. states where vaccination rates remained low in fall 2021. The experimental design is an RCT with 4 groups, randomized at the county level: 1) a control group which receives no intervention, 2) a treatment group in which Facebook users receive ads which include videos of health professionals telling them to get vaccinated, 3) a treatment group in which Facebook users receive ads which include videos of health professionals encouraging them to help their friends to get vaccinated, and 4) a treatment group in which Facebook users receive ads which include videos of health professionals encouraging them to get their most influential friends to help their friends get vaccinated. In treatments 3 and 4, participants will have the option to sign up to be a "vaccine ambassador," in which case they will get notifications when the study team posts new vaccine-related content, and will receive reminders about encouraging their friends to be vaccinated. The vaccine ambassadors will also be entered into a lottery to win prizes. The study team is building a website to host the videos of health professionals which answer common questions about Covid-19 vaccination. The investigators will measure engagement with the vaccine-related content as well as assess effects on vaccination rates at the county level.